{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:08:26Z","timestamp":1786579706521,"version":"build-2736575974"},"reference-count":121,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. Leading the list are glucagon-like peptide-1 receptor agonists (GLP1RAs), the first of which, exenatide, was approved by the FDA in 2005. Two other major classes of drugs have also entered the market: dipeptidyl peptidase-4 (DPP-4) inhibitors, commonly known as gliptins and approved in 2006, and sodium\u2013glucose cotransporter-2 (SGLT-2) inhibitors, with the first approval occurring in 2013. These drugs have revolutionized the treatment of diabetes. Additionally, on the horizon, the once-weekly basal insulin analog insulin icodec and the once-weekly combination of insulin icodec and semaglutide are expected to be available in the future. Beyond glycemic control, GLP1RAs have exhibited benefits in conditions associated with diabetes, including hypertension, dyslipidemia, non-alcoholic steatohepatitis, as well as in neurodegenerative diseases such as Alzheimer\u2019s disease. Additionally, emerging research suggests potential roles in certain types of cancer, infertility, and associative learning. Major cardiovascular events seem to be lower in patients on GLP1RAs. While some evidence is robust, other findings remain tenuous. It is important that clinicians are familiar with current research in order to provide optimal evidence-based care to patients. In the not-too-distant future, there may be a case to prescribe these drugs for benefits outside diabetes.<\/jats:p>","DOI":"10.3390\/jcm14061978","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T07:02:16Z","timestamp":1741935736000},"page":"1978","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss"],"prefix":"10.3390","volume":"14","author":[{"given":"Lalitha","family":"Sundararaman","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Brigham and Women\u2019s Hospital, 75 Francis St., Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divakara","family":"Gouda","sequence":"additional","affiliation":[{"name":"Inspira Health Network, 155 Bridgeton Pike ste c, Mullica Hill, NJ 08062, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Karnataka Institute of Endocrinology and Research Bangalore, Binnamangala, Stage 1, Indiranagar, Bengaluru 560038, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithra","family":"Sundararaman","sequence":"additional","affiliation":[{"name":"Prana Holistic Center for Fertility and Integrated Medicine, 74\/198, St\u2019Mary\u2019s Road, Opp. St\u2019 Mary\u2019s Church, Trustpakkam, Abiramapuram, Chennai 600018, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-0424","authenticated-orcid":false,"given":"Basavana","family":"Goudra","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Sidney Kimmel Medical College, Jefferson Health, 111 S 11th Street, #8280, Philadelphia, PA 19107, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"ref_1","first-page":"e41","article-title":"Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults with Body Mass Index \u226527 kg\/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy","volume":"81","author":"Linetzky","year":"2024","journal-title":"Hypertension"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/hep.26717","article-title":"Extrahepatic complications of nonalcoholic fatty liver disease","volume":"59","author":"Armstrong","year":"2014","journal-title":"Hepatol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00415-020-09813-4","article-title":"GLP-1 receptor agonists in diabetes for stroke prevention: A systematic review and meta-analysis","volume":"267","author":"Malhotra","year":"2020","journal-title":"J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2023.5573","article-title":"GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight\/Obesity","volume":"10","author":"Wang","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cub.2014.05.075","article-title":"Impaired associative learning with food rewards in obese women","volume":"24","author":"Zhang","year":"2014","journal-title":"Curr. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneur.58.2.186","article-title":"Synucleinopathies: Clinical and Pathological Implications","volume":"58","author":"Galvin","year":"2001","journal-title":"Arch. Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Zhou, L., Qu, H., Yang, L., and Shou, L. (2023). Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: A meta-analysis and systematic review. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01500-5"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11906-005-0089-x","article-title":"The salt paradox and its possible implications in managing hypertensive diabetic patients","volume":"7","author":"Vallon","year":"2005","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1524-6175.2005.04130.x","article-title":"The Role of the Kidneys in Hypertension","volume":"7","author":"Navar","year":"2007","journal-title":"J. Clin. Hypertens."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wajdlich, M., and Nowicki, M. (2024). The impact of GLP-1 receptor agonist liraglutide on blood pressure profile, hydration, natriuresis in diabetic patients with severely impaired kidney function. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-55724-z"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11906-015-0621-6","article-title":"GLP-1 Agonists and Blood Pressure: A Review of the Evidence","volume":"18","author":"Goud","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajh\/hpt196","article-title":"Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-analysis and meta-regression","volume":"27","author":"Katout","year":"2014","journal-title":"Am. J. Hypertens."},{"key":"ref_17","first-page":"751","article-title":"Hemodynamic effect of a single dose of glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide in patients with diabetic kidney disease","volume":"72","author":"Wajdlich","year":"2021","journal-title":"J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"F355","DOI":"10.1152\/ajprenal.00729.2010","article-title":"Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1","volume":"301","author":"Crajoinas","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11154-014-9287-7","article-title":"Effects of GLP-1 in the kidney","volume":"15","author":"Skov","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2174\/1573399810666140707092506","article-title":"Effect of GLP-1 based therapies on diabetic dyslipidemia","volume":"10","author":"Patel","year":"2014","journal-title":"Curr. Diabetes Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12933-017-0646-z","article-title":"Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes","volume":"17","author":"Lambadiari","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"635472","DOI":"10.1155\/2012\/635472","article-title":"Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: Effects on endothelial and vascular dysfunction beyond glycemic control","volume":"2012","author":"Forst","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1523\/JNEUROSCI.5977-08.2009","article-title":"Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity","volume":"29","author":"Nogueiras","year":"2009","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"G299","DOI":"10.1152\/ajpgi.90601.2008","article-title":"Stimulation of incretin secretion by dietary lipid: Is it dose dependent?","volume":"297","author":"Yoder","year":"2009","journal-title":"Am. J. Physiol. \u2014Gastrointest. Liver Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.atherosclerosis.2010.04.024","article-title":"One-year treatment with exenatide vs. insulin glargine: Effects on postprandial glycemia, lipid profiles, and oxidative stress","volume":"212","author":"Bunck","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2010.05.028","article-title":"Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus","volume":"212","author":"Schwartz","year":"2010","journal-title":"Atherosclerosis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.2337\/diabetes.50.3.609","article-title":"Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients","volume":"50","author":"Krarup","year":"2001","journal-title":"Diabetes"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2174\/1871529X14666140505125300","article-title":"Glucagon-like peptide-1 as a key regulator of lipid and lipoprotein metabolism in fasting and postprandial states","volume":"14","author":"Farr","year":"2014","journal-title":"Cardiovasc. Hematol. Disord. Drug Targets."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1007\/s00125-009-1611-5","article-title":"The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice","volume":"53","author":"Hsieh","year":"2010","journal-title":"Diabetologia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.brainresrev.2005.11.007","article-title":"Lipid metabolism in cognitive decline and dementia","volume":"51","author":"Panza","year":"2006","journal-title":"Brain Res. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1161\/ATVBAHA.114.304873","article-title":"Central Nervous System Regulation of Intestinal Lipoprotein Metabolism by Glucagon-Like Peptide-1 via a Brain-Gut Axis","volume":"35","author":"Farr","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pharmthera.2016.11.001","article-title":"Intensive LDL-cholesterol lowering therapy and neurocognitive function","volume":"170","author":"Banach","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12933-021-01366-8","article-title":"GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: An updated meta-analysis of eight CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-020-01133-1","article-title":"Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: A systematic review and meta-analysis","volume":"19","author":"Kesselheim","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_39","unstructured":"(2024, September 10). Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial\u2014The Lancet. Available online: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(18)32261-X\/abstract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11606-021-07105-9","article-title":"The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: A Systematic Review and Meta-Analysis","volume":"37","author":"Alexander","year":"2022","journal-title":"J. Gen. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/pst.429","article-title":"The potential for bias in reporting of industry-sponsored clinical trials","volume":"10","author":"Pyke","year":"2011","journal-title":"Pharm. Stat."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1177\/0141076820914242","article-title":"Sponsorship bias in clinical trials: Growing menace or dawning realisation?","volume":"113","author":"Jefferson","year":"2020","journal-title":"J. R. Soc. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3233\/JRS-2012-0574","article-title":"Sponsorship bias in clinical research","volume":"24","author":"Lexchin","year":"2012","journal-title":"Int. J. Risk Saf. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dsi23-0010","article-title":"Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action","volume":"37","author":"Younossi","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global Burden of Liver Disease: 2023 Update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatol"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.3748\/wjg.v24.i16.1748","article-title":"Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction","volume":"24","author":"Boland","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Cuevas, J., Lucano-Landeros, S., L\u00f3pez-Cifuentes, D., Santos, A., and Armend\u00e1riz-Borunda, J. (2022). Epidemiologic, Genetic, Pathogenic, Metabolic, Epigenetic Aspects Involved in NASH-HCC: Current Therapeutic Strategies. Cancers, 15, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC9818030\/.","DOI":"10.3390\/cancers15010023"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1007\/s00125-016-3952-1","article-title":"Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: Current approaches and future directions","volume":"59","author":"Cusi","year":"2016","journal-title":"Diabetologia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): A randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet. Med. J. Br. Diabet. Assoc."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: The LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial","volume":"52","author":"Vaag","year":"2009","journal-title":"Diabetologia"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/s42255-023-00859-y","article-title":"Liraglutide restores impaired associative learning in individuals with obesity","volume":"5","author":"Hanssen","year":"2023","journal-title":"Nat. Metab."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.neuron.2019.11.024","article-title":"Synergy of Distinct Dopamine Projection Populations in Behavioral Reinforcement","volume":"105","author":"Heymann","year":"2020","journal-title":"Neuron"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"(2023). 2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement., 19, 1598\u20131695.","DOI":"10.1002\/alz.13016"},{"key":"ref_62","unstructured":"Alzheimer\u2019s Disease and Dementia (2024, September 27). Congress Reaches Bipartisan Agreement on $100 Million Alzheimer\u2019s Research Funding Increase and Continued Investment in Alzheimer\u2019s Public Health Infrastructure. Available online: https:\/\/alz.org\/news\/2024\/congress-bipartisan-funding-alzheimers-research."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/nmt-2018-0004","article-title":"Role of epigenetics in Alzheimer\u2019s disease pathogenesis","volume":"8","author":"Stoccoro","year":"2018","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/cns.12404","article-title":"DPP-4 Inhibitor Linagliptin Attenuates A\u03b2-induced Cytotoxicity through Activation of AMPK in Neuronal Cells","volume":"21","author":"Kornelius","year":"2015","journal-title":"CNS Neurosci. Ther."},{"key":"ref_65","first-page":"1582","article-title":"Therapeutic targets of brain insulin resistance in sporadic Alzheimer\u2019s disease","volume":"4","year":"2012","journal-title":"Front. Biosci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer\u2019s disease","volume":"88","author":"Tong","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ncpneuro0124","article-title":"Therapy Insight: Type 2 diabetes mellitus and the risk of late-onset Alzheimer\u2019s disease","volume":"2","author":"Haan","year":"2006","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e089799","DOI":"10.1002\/alz.089799","article-title":"Evaluation of Novel GLP-1 analogue in the treatment of Alzheimer\u2019s disease","volume":"20","author":"Edison","year":"2025","journal-title":"Alzheimers Dement."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archneurol.2010.225","article-title":"Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes","volume":"68","author":"Baker","year":"2011","journal-title":"Arch. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2016.04.052","article-title":"Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3\u03b2 pathway in an amyloid \u03b2 protein induced alzheimer disease mouse model","volume":"783","author":"Qi","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Hunter, K., and H\u00f6lscher, C. (2012). Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci., 13.","DOI":"10.1186\/1471-2202-13-33"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J. Neurosci. Off. J. Soc. Neurosci."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kong, F., Wu, T., Dai, J., Zhai, Z., Cai, J., Zhu, Z., Xu, Y., and Sun, T. (2023). Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer\u2019s disease models: A systematic review and meta-analysis of preclinical studies. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1205207"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gejl, M., Gjedde, A., Egefjord, L., M\u00f8ller, A., Hansen, S.B., Vang, K., Rodell, A., Br\u00e6ndgaard, H., Gottrup, H., and Schacht, A. (2016). In Alzheimer\u2019s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front. Aging Neurosci., 8.","DOI":"10.3389\/fnagi.2016.00108"},{"key":"ref_76","unstructured":"Gardener, A., and American Brain Foundation (2024, October 04). Disease Connections: Alzheimer\u2019s and Parkinson\u2019s. Available online: https:\/\/www.americanbrainfoundation.org\/disease-connections-alzheimers-and-parkinsons\/."},{"key":"ref_77","unstructured":"(2024, October 04). The Link Between Inflammation & Early Parkinson\u2019s|Parkinson\u2019s Foundation 2023. Available online: https:\/\/www.parkinson.org\/blog\/science-news\/inflammation."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","article-title":"The protein kinase B\/Akt signalling pathway in human malignancy","volume":"14","author":"Nicholson","year":"2002","journal-title":"Cell Signal."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/DMSO.S48260","article-title":"Akt\/PKB activation and insulin signaling: A novel insulin signaling pathway in the treatment of type 2 diabetes","volume":"7","author":"Mackenzie","year":"2014","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_80","unstructured":"Hogg, E., Wu, T., Bresee, C., Wertheimer, J., Malatt, C., Tan, E., Pomeroy, H., Nuno, M., Wyse, R., and Tagliati, M. (2024, October 04). A Phase, II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson\u2019s Disease. Rochester, NY. Available online: https:\/\/papers.ssrn.com\/abstract=4212371."},{"key":"ref_81","first-page":"157","article-title":"Semaglutide is Neuroprotective and Reduces \u03b1-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson\u2019s Disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Park. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1038\/jcbfm.2011.51","article-title":"Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia","volume":"31","author":"Teramoto","year":"2011","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ene.13905","article-title":"Protection against stroke with glucagon-like peptide 1 receptor agonists: A systematic review and meta-analysis","volume":"26","author":"Barkas","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Shikatani","year":"2013","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice with Experimental Arterial Hypertension","volume":"40","author":"Frenis","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Krasner, N.M., Ido, Y., Ruderman, N.B., and Cacicedo, J.M. (2014). Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097554"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.neuropharm.2017.08.022","article-title":"Glucagon-like receptor 1 agonists and DPP-4 inhibitors: Anti-diabetic drugs with anti-stroke potential","volume":"136","author":"Darsalia","year":"2018","journal-title":"Neuropharmacology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1167\/iovs.15-19006","article-title":"Protective Effect of a GLP-1 Analog on Ischemia-Reperfusion Induced Blood-Retinal Barrier Breakdown and Inflammation","volume":"57","author":"Lin","year":"2016","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12974-019-1638-6","article-title":"The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke","volume":"16","author":"Shan","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1479164111404257","article-title":"A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-\/-mouse model","volume":"8","author":"Gaspari","year":"2011","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Trakoonsenathong, R., Kunprom, W., Aphivatanasiri, C., Yueangchantuek, P., Pimkeeree, P., Sorin, S., Khawkhiaw, K., Chiu, C.F., Okada, S., and Wongkham, S. (2024). Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-64774-2"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"384","DOI":"10.2337\/dc22-1148","article-title":"GLP-1 Receptor Agonists and the Risk of Thyroid Cancer","volume":"46","author":"Bezin","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Juji\u0107, A., Godina, C., Belting, M., Melander, O., Juul Holst, J., Ahlqvist, E., Gomez, M.F., Nilsson, P.M., Jernstr\u00f6m, H., and Magnusson, M. (2023). Endogenous incretin levels and risk of first incident cancer: A prospective cohort study. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-27509-3"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.2337\/db13-0822","article-title":"Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls","volume":"62","author":"Drucker","year":"2013","journal-title":"Diabetes"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/jnci\/89.18.1360","article-title":"Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark","volume":"89","author":"Wideroff","year":"1997","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","article-title":"The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells","volume":"132","author":"Ligumsky","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2337\/dc17-0280","article-title":"Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies","volume":"41","author":"Boniol","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"JCM (2024, September 10). Free Full-Text. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. Available online: https:\/\/www.mdpi.com\/2077-0383\/12\/18\/5915.","DOI":"10.3390\/jcm12185915"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1093\/humrep\/13.6.1502","article-title":"Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment","volume":"13","author":"Clark","year":"1998","journal-title":"Hum. Reprod."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.fertnstert.2012.04.012","article-title":"Body mass index and short-term weight change in relation to treatment outcomes in women undergoing assisted reproduction","volume":"98","author":"Chavarro","year":"2012","journal-title":"Fertil. Steril."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.fertnstert.2014.01.036","article-title":"A retrospective cohort study to evaluate the impact of meaningful weight loss on fertility outcomes in an overweight population with infertility","volume":"101","author":"Kort","year":"2014","journal-title":"Fertil. Steril."},{"key":"ref_105","first-page":"CD007506","article-title":"Lifestyle changes in women with polycystic ovary syndrome","volume":"2019","author":"Lim","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/dom.16042","article-title":"Semaglutide Improved Sperm Morphology in Obese Men with Type 2 Diabetes Mellitus and Functional Hypogonadism","volume":"27","author":"Jensterle","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Arillotta, D., Floresta, G., Guirguis, A., Corkery, J.M., Catalani, V., Martinotti, G., Sensi, S.L., and Schifano, F. (2023). GLP-1 Receptor Agonists and Related Mental Health Issues; Insights from a Range of Social Media Platforms Using a Mixed-Methods Approach. Brain Sci., 13.","DOI":"10.3390\/brainsci13111503"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e2423335","DOI":"10.1001\/jamanetworkopen.2024.23335","article-title":"GLP-1 Receptor Agonists and Suicidality\u2014Caution Is Needed","volume":"7","author":"Salvo","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: Reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"20451253231165169","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin\u2014A case series","volume":"13","author":"Prasad","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/YCO.0000000000000952","article-title":"GLP-1 receptor agonists and weight loss in schizophrenia\u2014Past, present, and future","volume":"37","author":"Trott","year":"2024","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/jgh.13808","article-title":"Glucagon-like peptide-1 analog, liraglutide, improves visceral sensation and gut permeability in rats","volume":"33","author":"Nozu","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"137397","DOI":"10.1016\/j.neulet.2023.137397","article-title":"GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model","volume":"812","author":"Jing","year":"2023","journal-title":"Neurosci. Lett."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/s12276-024-01342-8","article-title":"GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation","volume":"56","author":"Go","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_116","first-page":"121","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: A new opportunity?","volume":"32","author":"Meurot","year":"2022","journal-title":"J. Orthop. Transl."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Rowlands, J., Heng, J., Newsholme, P., and Carlessi, R. (2018). Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function. Front. Endocrinol., 9, Available online: https:\/\/www.frontiersin.org\/journals\/endocrinology\/articles\/10.3389\/fendo.2018.00672\/full.","DOI":"10.3389\/fendo.2018.00672"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00395-015-0465-x","article-title":"Gliptin and GLP-1 analog treatment improves survival and vascular inflammation\/dysfunction in animals with lipopolysaccharide-induced endotoxemia","volume":"110","author":"Steven","year":"2015","journal-title":"Basic Res. Cardiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s12325-020-01399-7","article-title":"Dysfunctional Coagulation in COVID-19: From Cell to Bedside","volume":"37","author":"Wang","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1161\/ATVBAHA.119.313645","article-title":"Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions","volume":"40","author":"Sternkopf","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","article-title":"The Effect of Semaglutide on Mortality and COVID-19-Related Deaths: An Analysis From the SELECT Trial","volume":"84","author":"Scirica","year":"2024","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1978\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:53:45Z","timestamp":1760028825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/6\/1978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":121,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14061978"],"URL":"https:\/\/doi.org\/10.3390\/jcm14061978","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]}}}